Skip to main content

$0.050 (0%)

High

$0.05

Low

$0.05

Trades

132

Turnover

$407,237

Volume

8,117,500
30 June 2023 at 3:59pm
Register to track ALA and receive email alerts.
Subject
ALA Ann: Notification regarding unquoted securities - ALA

ALA Ann: Proposed issue of securities - ALA

ALA Ann: ALA and IMU collaboration advances to next phase of testing

ALA Ann: Arovella to present at AACR conference

ALA Ann: Quarterly Appendix 4C and Activities Report

ALA Ann: Change in substantial holding

ALA Ann: Notice Under Section 708A

ALA Ann: Application for quotation of securities - ALA

ALA Ann: Notice Under Section 708A

ALA Ann: Application for quotation of securities - ALA

ALA Ann: Investor Presentation

ALA Ann: Proposed issue of securities - ALA

ALA Ann: AROVELLA COMPLETES $1.65M PLACEMENT

ALA Ann: Trading Halt

ALA Ann: Arovella Biotech Showcase Presentation

ALA Ann: Arovella appoints Chief Operating Officer

ALA Ann: Notification of cessation of securities - ALA

ALA Ann: ALA options cytokine technology to enhance iNKT platform

ALA Ann: Change of Director's Interest Notice x4

ALA Ann: Notification regarding unquoted securities - ALA

ALA Ann: Notice Under Section 708A

ALA Ann: Application for quotation of securities - ALA

ALA Ann: Proposed issue of securities - ALA

ALA Ann: Change of Director's Interest Notice

ALA Ann: Notice Under Section 708A

ALA Ann: Application for quotation of securities - ALA

ALA Ann: Application for quotation of securities - ALA

ALA Ann: Proposed issue of securities - ALA

ALA Ann: Proposed issue of securities - ALA

ALA Ann: R&D Tax Incentive refund received

ALA Ann: Results of Annual General Meeting

ALA Ann: AGM FY22 Presentation

ALA Ann: Arovella to present at Biotech Showcase 2023

ALA Ann: Europe Patent to be granted for iNKT Cell Therapy Platform

ALA Ann: Quarterly Appendix 4C and Activities Report

ALA Ann: Arovella to close its Perth OroMist R&D Facility

ALA Ann: Notice of Annual General Meeting/Proxy Form

ALA Ann: Appendix 4G

ALA Ann: Corporate Governance Statement

ALA Ann: Annual Report to shareholders

ALA Ann: ALA iNKT therapy and IMU onCARlytics - correction

ALA Ann: Investor Presentation Imugene Arovella Therapies

ALA Ann: Preclinical trial of ALA iNKT therapy and IMU onCARlytics

ALA Ann: Notice Under Section 708A

ALA Ann: Application for quotation of securities - ALA

ALA Ann: Proposed issue of securities - ALA

ALA Ann: Notification regarding unquoted securities - ALA

ALA Ann: Preliminary Final Report

ALA Ann: Application for quotation of securities - ALA

ALA Ann: Notification of cessation of securities - ALA

Register to track ALA and receive email alerts.